Orphan status for Mesoblast
Wednesday, 17 September, 2008
The US FDA has granted orphan drug designation for the use of adult stem cells developed by Mesoblast [ASX: MSB] in patients undergoing bone marrow transplantation.
Mesoblast's sister company Angioblast Systems has been granted the right to use its allogeneic mesenchymal precursor cells in patients with haematologic malignancies which have proven unresponsive to conventional chemotherapy.
The orphan drug designation is reserved for diseases affecting fewer than 200,000 patients annually.
It allows for an accelerated review process by the FDA, seven year exclusivity in the market and various tax benefits.
Bacteriophage cocktail to combat superbugs
Entelli-02 is a five-phage cocktail designed specifically to target Enterobacter cloacae...
Exclusive colostrum intake may reduce risk of food allergies
Newborns who are exclusively fed colostrum in the first 72 hours following birth are five times...
Sunscreen and supplements can lower your vitamin D levels
People who use SPF50+ sunscreen daily are more likely to be vitamin D deficient, while taking...
